Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth

Molecular Vision

Volumn 14, Issue , 2008, Pages 1752-1759

  el Filali, Mariam ^a   Homminga, Irene ^a   Maat, Willem ^a   van der Velden, Pieter A ^a   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

9(11)DEHYDROCORTISOL; AL 4940 06; CORTICOSTEROID; PIGMENT EPITHELIUM DERIVED FACTOR; T 6501; TETRAZOLIUM; THROMBOSPONDIN 1; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL COUNT; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR PROMOTION; UPREGULATION; UVEA MELANOMA;

ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE PROTEINS; HUMANS; MELANOMA; NERVE GROWTH FACTORS; PREGNADIENEDIOLS; SERPINS; THROMBOSPONDIN 1; TRIAMCINOLONE ACETONIDE; UVEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53749101548     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32:239-51.
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:956-61.
3. Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 2005; 140:612-7.
4. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E. EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology 2007; 114:2309-15.
5. Bergman L, Seregard S, Nilsson B, Lundell G, Ringborg U, Ragnarsson-Olding B. Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 2003; 44:3282-7.
6. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:962-5.
7. Augsburger JJ, Correa ZM, Freire J, Brady LW. Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 1998; 105:1670-8.
8. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44:4651-9.
9. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72:2219-23.
10. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005; 23:8076-80.
11. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996; 41:215-28.
12. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222-5.
13. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997; 19:22-8.
14. Damato B. Developments in the management of uveal melanoma. Clin Experiment Ophthalmol 2004; 32:639-47.
15. Pötter R, Janssen K, Prott FJ, Widder J, Haverkamp U, Busse H, Müller RP. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: evaluation of 175 patients treated with 150 Gy from 1981-1989. Front Radiat Ther Oncol 1997; 30:143-9.
16. Bartlema YM, Oosterhuis JA, Journee-De Korver JG, Tjho-Heslinga RE, Keunen JE. Combined plaque radiotherapy and transpupillary thermotherapy in choroidal melanoma: 5 years' experience. Br J Ophthalmol 2003; 87:1370-3.
17. Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Dendale R, Delacroix S, Nauraye C, Estève M, Plancher C, Asselain B. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res 2006; 38:255-60.
18. Archer DB, Amoaku WM, Gardiner TA. Radiation retinopathy-clinical, histopathological, ultrastructural and experimental correlations. Eye 1991; 5:239-51.
19. Zamber RW, Kinyoun JL. Radiation retinopathy. West J Med 1992; 157:530-3.
20. Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2005; 89:730-8.
21. Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999; 117:609-14.
22. Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (avastin. for radiation retinopathy. Arch Ophthalmol 2007; 125:751-6.
23. Er H, Yilmaz H. Intravitreal cortisone injection for refractory diffuse diabetic macular edema. Ophthalmologica 2005; 219:394-400.
24. Patelli F, Fasolino G, Radice P, Russo S, Zumbo G. DI Tizio FM, Frisone G, Marchi S. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 2005; 25:840-5.
25. Sorensen TL, Haamann P, Villumsen J, Larsen M. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Acta Ophthalmol Scand 2005; 83:67-70.
26. Jonas JB, Spandau UH, Kamppeter BA, Harder B. Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye 2007; 21:387-94.
27. Shields CL, Demirci H, Dai V, Marr BP, Mashayekhi A, Materin MA, Manquez ME, Shields JA. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina 2005; 25:868-74.
28. Pe'er J, Stefani FH, Seregard S, Kivela T, Lommatzsch P, Prause JU, Sobottka B, Damato B, Chowers I. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study. Br J Ophthalmol 2001; 85:1208-12.
29. Harbour JW, Char DH, Kroll S, Quivey JM, Castro J. Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. Ophthalmology 1997; 104:1785-92.
30. Murata M, Shimizu S, Horiuchi S, Taira M. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2006; 244:205-9.
31. Hashimoto I, Nakanishi H, Shono Y, Toda M, Tsuda H, Arase S. Angiostatic effects of corticosteroid on wound healing of the rabbit ear. J Med Invest 2002; 49:61-6.
32. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol 1993; 231:34-40.
33. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3:65-71.
34. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76.
35. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69:4-10.
36. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285:245-8.
37. Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004; 88:809-15.
38. Trotter MJ, Colwell R, Tron VA. Thrombospondin-1 and cutaneous melanoma. J Cutan Med Surg 2003; 7:136-41.
39. Jaissle GB, Szurman P, Bartz-Schmidt KU. Ocular side effects and complications of intravitreal triamcinolone acetonide injection.
40. Clark AF, Mellon J, Li XY, Ma D, Leber H, Apte R, Alizadeh H, Hegde S, McLenaghan A, Mayhew E, D'Orazio TJ, Niederkorn JY. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 1999; 40:2158-62.
41. Schmidt-Erfurth U, Michels S, Michels R, Aue A. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 2005; 15:482-5.
42. De Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoom E, Beverstock G, Danen EH, Jager MJ. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 1995; 62:155-61.
43. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 1989; 30:829-34.
44. Nareyeck G, Zeschnigk M, Prescher G, Lohmann DR, Anastassiou G. Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3. Exp Eye Res 2006; 83:858-64.
45. Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs 1997; 6:1867-77.
46. Narayanan R, Kenney MC, Kamjoo S, Trinh TH, Seigel GM, Resende GP, Kuppermann BD. Trypan blue: effect on retinal pigment epithelial and neurosensory retinal cells. Invest Ophthalmol Vis Sci 2005; 46:304-9.
47. Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJ, Singh AD, Frants RR, Jager MJ, Gruis NA. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer 2003; 89:1914-9.
48. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25:169-93.
49. Gilsbach R, Kouta M, Bonisch H, Bruss M. Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. Biotechniques 2006; 40:173-7.
50. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005; 85:154-9.
51. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of realtime quantitative PCR data. Genome Biol 2007; 8:R19.
52. Yeung CK, Chan KP, Chan CK, Pang CP, Lam DS. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol 2004; 48:236-42.
53. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005; 46:1062-8.
54. Spandau UH, Sauder G, Schubert U, Hammes HP, Jonas JB. Effect of triamcinolone acetonide on proliferation of retinal endothelial cells in vitro and in vivo. Br J Ophthalmol 2005; 89:745-7.
55. Valamanesh F, Torriglia A, Savoldelli M, Gandolphe C, Jeanny JC, BenEzra D, Behar-Cohen F. Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Mol Vis 2007; 13:1746-57.
56. Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci 2005; 46:4336-41.
57. Gao H, Qiao X, Gao R, Mieler WF, McPherson AR, Holz ER. Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina. Vision Res 2004; 44:349-56.
58. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 2002; 8:330-4.
59. Yang H, Xu Z, Iuvone PM, Grossniklaus HE. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF. to pigment epithelium derived factor (PEDF. RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis 2006; 12:511-7.
60. Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem 2006; 39:267-76.
61. Hosomichi J, Yasui N, Koide T, Soma K, Morita I. Involvement of the collagen I-binding motif in the anti-angiogenic activity of pigment epithelium-derived factor. Biochem Biophys Res Commun 2005; 335:756-61.
62. Streck CJ, Zhang Y, Zhou J, Ng C, Nathwani AC, Davidoff AM. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J Pediatr Surg 2005; 40:236-43.
63. Garcia M, Fernandez-Garcia NI, Rivas V, Carretero M, Escamez MJ, Gonzalez-Martin A, Medrano EE, Volpert O, Jorcano JL, Jimenez B, Larcher F, Del Rio M. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004; 64:5632-42.
64. Tsuru M, Arima N, Toyozumi Y, Kato S. Pigment epithelium-derived factor as a new diagnostic marker for melanocytic tumors. Kurume Med J 2005; 52:81-7.
65. Apte RS, Barreiro RA, Duh E, Volpert O, Ferguson TA. Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest Ophthalmol Vis Sci 2004; 45:4491-7.
66. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006; 1765:178-88.
67. Vedoy CG, Sogayar MC. Isolation and characterization of genes associated with the anti-tumor activity of glucocorticoids. Brain Res Mol Brain Res 2002; 106:57-69.
68. Leclerc N, Luppen CA, Ho VV, Nagpal S, Hacia JG, Smith E, Frenkel B. Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol 2004; 33:175-93.
69. van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ. Promoter hypermethylation: a common cause of reduced p16(INK4a. expression in uveal melanoma. Cancer Res 2001; 61:5303-6.
70. Ma D, Gerard RD, Li XY, Alizadeh H, Niederkorn JY. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1. in an athymic mouse model. Blood 1997; 90:2738-46.